GI 181771

GI 181771 is a cholecystokinin 1 receptor agonist investigated for the treatment of obesity.

Signaling Pathways >> GPCR/G Protein >> Cholecystokinin Receptor

Research Areas >> Metabolic Disease

Target: Cholecystokinin 1 receptor[1]

[1]. Myer JR, et al. Species- and dose-specific pancreatic responses and progression in single- and repeat-dose studies with GI181771X: a novel cholecystokinin 1 receptor agonist in mice, rats, and monkeys. Toxicol Pathol. 2014 Jan;42(1):260-74.

[2]. Roses AD, et al. Stimulation of cholecystokinin-A receptors with Gl181771X: a failed clinical trial that did not test the pharmacogenetic hypothesis for reduction of food intake. Clin Pharmacol Ther. 2009 Apr;85(4):362-5.

Caerulein ammonium salt | Gastrin I (human) | Nastorazepide | Loxiglumide | Proglumide | Sograzepide | Tarazepide | CCK-A receptor inhibitor 1 | CCK-B Receptor Antagonist 1 | 1H-Indole-2-carboxamide, N-[(3R)-1-(2-fluorophenyl)-3,4,6,7-tetrahydro-4-oxopyrrolo[3,2,1-jk][1,4]benzodiazepin-3-yl]- | Gastrin/CCK antagonist 1 | Mini Gastrin I, human | SR 146131